Duration of chemotherapy for metastatic breast cancer: A systematic review and meta-analysis of randomized clinical trials
Journal of Clinical Oncology, 04/08/2011
Gennari A et al.
– Longer first-line chemotherapy duration is associated with marginally longer OS and a substantially longer PFS.
Searched literature databases to identify randomized controlled trials that compared different chemotherapy durations in first-line treatment of MBC
Only trials with unconfounded comparisons of additional cycles of chemotherapy included
Main outcome measures for this analysis OS and PFS
Published data from retrieved studies analyzed according to standard meta-analytic techniques
11 randomized clinical trials including 2,269 patients
Longer first-line chemotherapy duration resulted in significantly improved OS (HR 0.91; 95% CI, 0.84 to 0.99) and PFS (HR, 0.64; 95% CI, 0.55 to 0.76)
No differences in effects on either OS or PFS between subgroups defined by time of random assignment, study design, number of chemotherapy cycles in control arm or concomitant endocrine therapy